11 results about "Increased Ocular Pressure" patented technology

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention relates to the technical field of animal disease models, and discloses a construction method of an intraocular hypertension animal model, comprising the following steps: step A, selecting an experimental animal; step B, preparing experimental instruments and reagents; c, in an anesthesia mode, deep anesthesia is carried out on the animal, and subsequent deep anesthesia is carried out; d, intraocular pressure measurement, wherein the basic intraocular pressure value is measured through anterior chamber injection. Step E, performing anterior chamber injection, and using ofloxacin antibiotic oculentum to prevent infection after an operation; and F, intraocular pressure measurement: measuring the change of the intraocular pressure value after the anterior chamber injection. According to the method, the natural pathological process of open-angle glaucoma is simulated by injecting IFN-beta into the anterior chamber, the situation that acute intraocular pressure rise is caused mainly by blocking an aqueous humor flow outlet channel like other models is avoided, and the method can better reflect the real situation of glaucoma diseases; in addition, the model avoids intraocular pressure change caused by anatomical structure change, so that the accuracy and reliability of the model are improved.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

Provided herein are inhibitory nucleic acids (e.g., artificial microRNAs) and rAAV vectors targeting Ras homolog family member A (RhoA) and uses of the same for treating conditions related to increased intraocular pressure (IOP) (e.g., glaucoma).

The present disclosure pertains to the phakic refractive lenses such as toric lenses, an advanced posterior chamber floating phakic refractive lens (PRL) designed for the correction of severe refractive errors, including myopia, hyperopia, and astigmatism. This innovative lens can reduce or minimize complications commonly associated with traditional phakic intraocular lenses, such as intraocular pressure elevation, cataract formation, and iris pigment dispersion. The phakic refractive lenses such as the toric lenses described herein feature a buoyant, flexible structure with a central aperture to facilitate aqueous humor flow, creating a natural centering force that stabilizes the lens within the pupillary space.

The application discloses a teaching simulative human eyeball aqueous humor circulation model in the technical field of eyeball aqueous humor circulation models, which comprises a model box, an eyeball model assembly arranged in the model box, a functional body arranged at the top of the model box and a pump assembly arranged in the functional body. The eyeball model assembly comprises an eyeball wall, an eyeball and an optic nerve, and the eyeball wall is provided with a cornea at the front end. An iris is arranged on the side of the cornea close to the eyeball, the space between the cornea and the iris is an anterior chamber, the included angle between the cornea and the iris is an anterior chamber angle, the center of the iris is provided with a pupil, the iris is provided with a lens on the side close to the eyeball, the lens is provided with a zonular ligament around the lens, and the other end of the zonular ligament is fixedly connected with a ciliary body. The space between the iris and the lens constitutes a posterior chamber. The application has the advantages of simple structure, simulation of the process that the aqueous humor is retained in the eye to press the optic nerve when the anterior chamber angle is closed or the aqueous humor outflow passage is blocked, and convenience for medical students to understand the process that the optic nerve is pressed by the increased intraocular pressure when the aqueous humor passage is blocked.

The present invention relates to iota-carrageenan for use as a main or sole active ingredient in an aqueous pharmaceutical composition for the prevention or treatment of non-viral non-allergic clinically relevant eye conditions affecting at least one of mucosal tissues at or around an individual's eye, an eye surface, corneal tissue, and fluid inside the eye, said clinically relevant eye conditions selected from the group consisting of increased intraocular pressure, non- allergic and non-viral conjunctivitis, irritations caused by airborne particulate matter other than allergens, and late complications of non-viral and non-allergic conjunctivitis selected from the group consisting of corneal opacities, subepithelial infiltrates, and formation of ocular pseudomembranes.

The present invention discloses an intraocular pressure elevation teaching device, which includes a main cavity, a simulated vitreous body, a simulated lens, a simulated iris, a simulated ciliary body, a first injection tube, and an indicating cavity. The simulated vitreous body is arranged in the main cavity, the simulated lens and the simulated ciliary body are arranged on the front side of the simulated vitreous body, the simulated iris is arranged on the front side of the simulated lens and the simulated ciliary body and is connected to the simulated ciliary body, and a posterior chamber is formed between the simulated iris and the simulated lens. The simulated iris includes a first simulated iris, the inner side of the first simulated iris for forming the pupil is hermetically connected to the simulated lens, and the first posterior chamber formed between the first simulated iris and the simulated lens is not communicated with other parts of the posterior chamber; the first posterior chamber is communicated with the main cavity, a first injection tube communicated with the first posterior chamber is arranged in the simulated ciliary body of the first posterior chamber, and an indicating cavity communicated with the main cavity is arranged on the simulated vitreous body. Using this intraocular pressure elevation teaching device can simulate and demonstrate the principle of intraocular pressure elevation.

The utility model discloses a head lowering alarm device for preventing and controlling myopia by preventing intraocular pressure from rising. The head lowering alarm device comprises an elastic attaching part, a first resistance transmission sheet, a second resistance transmission sheet, a first sliding contact, a second sliding contact, a signal processing module and a wireless module. The fitting part is used for fitting the rear neck of a human body; one end of the first resistor transmission sheet and one end of the second resistor transmission sheet are both fixed to the attaching component, and the first resistor transmission sheet and the second resistor transmission sheet are arranged in an up-down staggered mode; the first sliding contact is arranged at the other end of the first resistance transmission sheet and is in contact with the second resistance transmission sheet; the sliding contact II is arranged at the other end of the resistor transmission sheet II and is in contact with the resistor transmission sheet I; the corresponding ends of the signal processing module are electrically connected with the first sliding contact and the second sliding contact. The corresponding end of the wireless module is electrically connected with the corresponding end of the signal processing module. The device is in a neck sticking form, and is convenient to wear, small in size and comfortable to wear.

The invention provides application of kushenone in preparation of a product for preventing and / or treating glaucoma, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the kushenone has the effect of preventing and / or treating glaucoma for the first time, can be used as a candidate medicine for treating acute glaucoma, can prevent ischemia reperfusion injury caused by acute intraocular pressure rise, and has the effect of inhibiting ferroptosis so as to play a role in protecting retinal ganglion cells; an effect can be achieved by inhibiting a cGAS-STING pathway and LCN2 expression, so that ferroptosis of microglial cells is inhibited.